EMILY SKEETERS: Open Payments
NPI 1467786848 · INDIANAPOLIS, IN. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$980 in 41 payments from 11 companies in 2025. Trend: 2023 $738 · 2024 $479 · 2025 $980
Food & beverage: $980
| Company | Payments | Amount |
|---|---|---|
| Astellas Pharma US Inc | 14 | $323 |
| MILLICENT US INC | 6 | $117 |
| MAYNE PHARMA COMMERCIAL LLC | 6 | $115 |
| ABBVIE INC. | 1 | $113 |
| Sumitomo Pharma America, Inc. | 3 | $86 |
| Exeltis, USA Inc. | 4 | $76 |
| Biogen, Inc. | 3 | $65 |
| Organon LLC | 1 | $30 |
| Bayer Healthcare Pharmaceuticals Inc. | 1 | $20 |
| Dexcom, Inc. | 1 | $20 |
Products named: Veozah, VRAYLAR, MYFEMBREE, FEMLYV, SLYND, ZURZUVAE, INTRAROSA, NEXPLANON.
Industry payments across IN — which companies pay providers there.
